Figure 2.

Profile of the IC₅₀ values of the approved proteasome inhibitors in different hematological malignancies. (A) Comparison of IC₅₀ values of bortezomib determined 48 h after the continuous treatment in various hematological malignancies, data represent mean ± SD. (B) Comparison of IC₅₀ values of carfilzomib determined 48 h after the continuous treatment in various hematological malignancies, data represent mean ± SD. In all analyses, statistical significance was obtained with ANOVA and Tukey’s multiple comparison test, where * represents p < 0.05 and **** represents p < 0.0001. AML = acute myeloid leukemia, B-ALL = B-cell acute lymphoblastic leukemia, B-CLL = B-cell chronic lymphocytic leukemia, MM = multiple myeloma, PCL = plasma-cell leukemia, PBMC = peripheral blood mononuclear cells, BTZ = bortezomib; CFZ = carfilzomib.